Nuvig: $161 Million (Series B) Raised To Develop Novel Immunomodulatory Therapeutics
By Amit Chowdhry ● Dec 8, 2024
Nuvig Therapeutics - a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases - announced the closing of a $161 million Series B round. The funding was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture Partners, with participation from new investors, B Capital, Leaps by Bayer, Global BioAccess Fund, LOTTE Holdings, Alexandria Venture Investments, and funds managed by abrdn, and existing shareholders, Novo Holdings A/S, Platanus, Bristol Myers Squibb, Digitalis Ventures, and Mission BioCapital.